ArticleAmerican journal of nuclear medicine and molecular imaging2017
The value of FDG PET/CT for follow-up of patients with melanoma: a retrospective analysis.
Article in American journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Review
- Article
- FDG PET Hybrid Imaging.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Organ-specific accuracy of [Japanese journal of radiology · 2024Article
- Comparison of large language models in management advice for melanoma: Google's AI BARD, BingAI and ChatGPT.Skin health and disease · 2024Article
- Diagnostic Performance of [Cancers · 2024Review
- Prognostic Value of BaselineCancers · 2023Article
- Whole-Body Imaging for the Primary Staging of Melanomas-A Single-Center Retrospective Study.Cancers · 2023Article
- Intrathymic Localization of Melanoma: A Brief Report of Two Cases and a Review of the Literature.Diagnostics (Basel, Switzerland) · 2023Article
- Article
- Precision Nuclear Medicine: The Evolving Role of PET in Melanoma.Radiologic clinics of North America · 2021Review
- Oncologic significance of unexpected osseous foci on FDG-PET without correlative CT abnormalities.Annals of nuclear medicine · 2021Article
- Influence ofEuropean journal of nuclear medicine and molecular imaging · 2020Article
- Melanoma Radiological Surveillance: A Review of Current Evidence and Clinical Challenges.The Yale journal of biology and medicine · 2020Review
- CD146-Targeted Multimodal Image-Guided Photoimmunotherapy of Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Article
- Recurrence of Melanoma After Initial Treatment: Diagnostic Performance of FDG PET in Posttreatment Surveillance.Nuclear medicine and molecular imaging · 2018Article
- Innocent PET avidity in patient with metastatic melanoma.BMJ case reports · 2018Article
- Multi-level otsu method to define metabolic tumor volume in positron emission tomography.American journal of nuclear medicine and molecular imaging · 2018Article
- Surveillance After a Previous Cutaneous Melanoma Diagnosis: A Scoping Review of Melanoma Follow-Up Guidelines.Journal of cutaneous medicine and surgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of melanoma (MM) is among the fastest rising cancers in the western countries. Positron Emission Tomography with Computed Tomography (PET/CT) is a valuable non-invasive tool for the diagnosis and staging of patients with MM. However, research on the value of PET/CT in follow-up of melanoma patients is limited. This study assesses the diagnostic value of PET/CT for follow-up after melanoma surgery. This retrospective study includes patients with MM who performed at least one PET/CT scan after initial surgery and staging. PET/CT findings were compared to histology, MRI or fine needle aspiration (FNA) to estimate the diagnostic accuracy. The diagnostic performance of PET/CT performed in patients with and without a clinical suspicion of relapse was compared. 238 patients (526 scans) were included. Of the 526 scans 130 (25%) scans were PET-positive, 365 (69%) PET-negative, and 28 (5%) had equivocal findings. Sensitivity was 89% [0.82-0.94], specificity 92% [0.89-0.95], positive and negative predictive values of 78% [0.70-0.84] and 97% [0.94-0.98] respectively. When stratified for reason of referral there was no statistical significant difference in the diagnostic accuracy of PET/CT between patients referred with or without a clinical suspicion of relapse. This study demonstrates that PET/CT despite a moderate sensitivity has a high negative predictive value in the follow-up of melanoma patients. Thus, a negative PET/CT-scan essentially rules out relapse. However, the frequency of false positive findings is relatively high, especially among patients undergoing a "routine" PET/CT with no clinical suspicion of relapse, potentially causing anxiety and leading to further diagnostic procedures.
Indexed as
Identifiers
29348980PMC5768920W2988285788What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.